High-throughput Screening Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The high-throughput screening market studied was anticipated to grow with a CAGR of nearly 7.8% during the forecast period. The high-throughput screening (HTS) centers in the public domain have increased significantly over the past decade, ranging in size, from modestly-equipped academic screening centers to well-endowed molecular libraries probe centers network (MLPCN). These centers facilitate a comprehensive approach to probe discovery in academia, and utilize, both, standard and innovative assay technologies for executing primary and secondary screening campaigns. One of the significant advantages of these centers was knowledge sharing among scientists, researchers, etc. In European countries, EU-open-screen, European counterpart of US NIH initiative, is also working to get open access to all European organizations involved in chemical biology. Additionally, the association of HTS centers is also emerging, which is aimed at sharing valuable information about the compound or target, or the whole process. The open access provides a better platform for knowledge sharing, and can help optimize the entire process, which may drive the demand for HTS technology among end users.
HTS systems allow tens of thousands or even hundreds of thousands of compounds to be evaluated in a single day. As the throughput increases, the amount of data for each experiment increases, and scientists analyze and derive results from large amounts of data. Due to the sheer number of samples being processed and the massive volume of data being produced, the need for extensive automation techniques arises, to streamline the operations. However, automation requires massive investments for the establishment of machinery and supporting architecture, which are roadblocks for small- and moderate-size research institutes. Thus, the high costs associated with automation techniques can limit the market expansion.
Scope of the Report
The high-throughput screening market has been segmented by technology, applications, products and services, end user, and geography. By technology, the market is divided into an ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology. By application, the market has been subdivided into target identification, primary screening, and toxicology. By products and services, the market has been segmented into instruments, reagents and kits, and services. By end user, the market has been segmented into pharmaceutical and biotechnology firms, academia and research institutes, and contract research organizations.
|By Products and Services|
|Reagents and Kits|
|By End User|
|Pharmaceutical and Biotechnology Firms|
|Academia and Research Institutes|
|Contract Research Organizations|
Key Market Trends
Pharmaceutical and Biotechnology Firms Represent the Largest End Users of High-throughput Screening Modalities.
In order to gain sustainable competitive advantage, most of the large and small biotechnology and pharmaceutical companies are focusing on the development of novel molecules for the treatment of several chronic conditions. Furthermore, FDA’s Center for Drug Evaluation and Research’s (CDER’s) new drug therapy approvals helped a wide range of patients suffering from many different medical conditions. The need for rapid and precise screening of several target molecules, during drug discovery and development phases, has led to the adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes. Since an automated HTS system can test 10,000 to 100,000 target compounds per day, and uHTS can test more than 100,000 compounds per day, their adoption for drug discovery and development process has resulted in the market expansion.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market
North America dominates the global high-throughput screening market, owing to the high adoption rate of HTS in the United States. The growth of the US high-throughput screening market can be attributed to the significant advances in combinatorial chemistry and the field of genomics. In addition, huge investments by the pharmaceutical industry, for HTS technologies, in terms of automation, miniaturization, and assay methodology, have further helped in the growth of the market.
To understand geography trends, Download Sample Report
The high-throughput screening market is highly competitive and consists of several major players. Most of the major players enjoy a global presence, and are facing intense competition in emerging economies. The emerging countries are becoming hotspots of significant competition, due to a rapidly expanding market size, fueled by growing investments in R&D and the recent trend of contract research outsourcing.
In June 2021, Bio-Rad Laboratories, Inc. partners with Seegene, Inc., for the clinical development and commercialization of infectious disease molecular diagnostic products and expand its presence in the high-throughput screening market.
In March 2020, Danaher Corporation acquired the Biopharma business from General Electric Company's Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Open Access to High-throughput Screening Laboratories
4.2.2 Technological Advancements in HTS
4.2.3 Increasing Usage in Universities and Research Centers
4.3 Market Restraints
4.3.1 High Capital Investment
4.3.2 Need for Extensive Automation Techniques
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Technology
5.1.1 Ultra-high-throughput Screening
5.1.2 Cell-based Assays
5.1.4 Label-free Technology
5.2 By Applications
5.2.1 Target Identification
5.2.2 Primary Screening
5.3 By Products and Services
5.3.2 Reagents and Kits
5.4 By End User
5.4.1 Pharmaceutical and Biotechnology Firms
5.4.2 Academia and Research Institutes
5.4.3 Contract Research Organizations
5.5.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.5.4 Middle-East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East & Africa
5.5.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Axxam SpA
6.1.3 Beckman Coulter Inc.
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Danaher Corporation
6.1.6 GE Healthcare
6.1.7 Merck KGaA
6.1.8 PerkinElmer Inc.
6.1.9 Tecan Group Ltd
6.1.10 Thermo Fisher Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The High-throughput Screening Market market is studied from 2018 - 2026.
What is the growth rate of High-throughput Screening Market?
The High-throughput Screening Market is growing at a CAGR of 7.8% over the next 5 years.
Which region has highest growth rate in High-throughput Screening Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in High-throughput Screening Market?
North America holds highest share in 2021.
Who are the key players in High-throughput Screening Market?
Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Thermo Fisher Scientific Inc. are the major companies operating in High-throughput Screening Market.